Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · ARQT · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
82
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Arcutis Biotherapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
ARQT insider buying and selling by quarter
ARQT insider selling · ARQT insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · ARQT ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
ARQT executive sell shares · ARQT board member insider trading · ARQT insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 11, 2026 | Vairavan Latha SVP Chief Financial Officer | Sale | 435 | $9K | Form 4 |
| May 11, 2026 | Burnett Patrick See Remarks | Sale | 222 | $5K | Form 4 |
| May 4, 2026 | Matsuda Masaru See Remarks | Sale | 7,372 | $172K | Form 4 |
| May 4, 2026 | Matsuda Masaru See Remarks | Sale | 884 | $21K | Form 4 |
| May 4, 2026 | Burnett Patrick See Remarks | Sale | 684 | $16K | Form 4 |
| May 4, 2026 | Vairavan Latha SVP Chief Financial Officer | Sale | 1,341 | $32K | Form 4 |
| May 4, 2026 | Watanabe Todd See Remarks · Director | Sale | 3,172 | $75K | Form 4 |
| May 1, 2026 | Welgus Howard G. Director | Sale | 7,144 | $164K | Form 4 |
| Apr 1, 2026 | Welgus Howard G. Director | Sale | 10,000 | $239K | Form 4 |
| Mar 2, 2026 | Leonard Keith R Director | Option | 12,220 | $92K | Form 4 |
| Mar 2, 2026 | Leonard Keith R Director | Option | 27,052 | $233K | Form 4 |
| Mar 2, 2026 | Leonard Keith R Director | Sale | 39,272 | $997K | Form 4 |
| Mar 2, 2026 | Welgus Howard G. Director | Sale | 10,000 | $257K | Form 4 |
| Feb 27, 2026 | Edwards Larry Todd See Remarks | Award | 30,000 | — | Form 4 |
| Mar 2, 2026 | Edwards Larry Todd See Remarks | Sale | 3,584 | $90K | Form 4 |
| Mar 2, 2026 | Edwards Larry Todd See Remarks | Sale | 103 | $3K | Form 4 |
| Feb 27, 2026 | Watanabe Todd See Remarks · Director | Award | 102,000 | — | Form 4 |
| Mar 2, 2026 | Watanabe Todd See Remarks · Director | Sale | 36,281 | $913K | Form 4 |
| Mar 2, 2026 | Watanabe Todd See Remarks · Director | Sale | 1,068 | $28K | Form 4 |
| Feb 27, 2026 | Matsuda Masaru See Remarks | Award | 37,000 | — | Form 4 |
| Feb 27, 2026 | Matsuda Masaru See Remarks | Sale | 3,325 | $93K | Form 4 |
| Mar 2, 2026 | Matsuda Masaru See Remarks | Sale | 6,553 | $165K | Form 4 |
| Mar 2, 2026 | Matsuda Masaru See Remarks | Sale | 193 | $5K | Form 4 |
| Mar 2, 2026 | Matsuda Masaru See Remarks | Sale | 1,987 | $51K | Form 4 |
| Feb 27, 2026 | Vairavan Latha SVP Chief Financial Officer | Award | 27,000 | — | Form 4 |
Vairavan Latha
SVP Chief Financial Officer
Date
May 11
Shares
435
Price
$21.05
Value
$9K
Vairavan Latha
SVP Chief Financial Officer
Date
May 4
Shares
1,341
Price
$23.61
Value
$32K
Watanabe Todd
See Remarks · Director
Date
May 4
Shares
3,172
Price
$23.61
Value
$75K
Watanabe Todd
See Remarks · Director
Date
Mar 2
Shares
36,281
Price
$25.16
Value
$913K
Watanabe Todd
See Remarks · Director
Date
Mar 2
Shares
1,068
Price
$25.91
Value
$28K
Vairavan Latha
SVP Chief Financial Officer
Date
Feb 27
Shares
27,000
Price
—
Value
—
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About ARQT insider trading
ARQT insider trades
Arcutis Biotherapeutics, Inc. (ARQT) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Burnett Patrick (See Remarks), Matsuda Masaru (See Remarks), Watanabe Todd (See Remarks · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. ARQT insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Arcutis Biotherapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
ARQT insider trading · 5 questionsThe insiders of Arcutis Biotherapeutics, Inc. (ARQT) include executives and directors such as Burnett Patrick (See Remarks), Matsuda Masaru (See Remarks), Watanabe Todd (See Remarks · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026